Company Product Description Indication Status
Phase I
Immutep Ltd., of Sydney Eftilagimod alpha Soluble LAG-3-Ig fusion protein Metastatic breast cancer EOC Pharma completed patient recruitment in the study being conducted in China
Phase II
Axsome Therapeutics Inc., of New York AXS-05 (dextromethorphan + bupropion) NMDA receptor antagonist; nicotinic acetylcholine receptor antagonist; opioid receptor sigma agonist 1 Alzheimer’s disease agitation Accelerating the completion of the Advance-1 phase II/III trial; top-line results now expected in early second quarter of 2020
Theralase Technologies Inc., of Toronto TLD-1433 Light-activated photodynamic compound Non-muscle invasive bladder cancer Notified by all of its Canadian clinical study sites that enrollment of new patients and conducting the first treatment procedure has been temporarily placed on hold pending resolution of the COVID-19 global pandemic

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments